remodel trial semaglutide Long-term kidney outcomes of in obesity and cardiovascular disease in the SELECT FLOWing with the SemagluTIDE —

MMN improvement was observed in the absence of robust changes in assessments of clinical severity, though the latter was observed in a larger and more prolonged clinical study

Int J Env Res Pub He (2020) 17(10):3664

Ozempic is approved for type 2 diabetes (0.25 mg to 2 mg), while Wegovy is approved for chronic weight management (up to 2.4 mg) and to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either overweight or obesity Exenatide extended-release (Bydureon BCise) : Once-weekly injection using microsphere technology Liraglutide (Victoza, Saxenda) : Once-daily injection

Given that CoQ10 supplementation is typically used for non-urgent indications rather than essential medical treatment, a cautious approach is reasonable